FDA orders recall of thyroid drug due to reduced effectiveness By Janderson Luiz
3 min read
 |
The United States Food and Drug Administration (FDA) has announced the recall of a common thyroid medication, levothyroxine sodium tablets, after being classified as “subpotent.” The decision was made on July 13, 2026 and implies that the medicine has an insufficient amount of active ingredient, making it less effective for patients who depend on it.
The recall is classified as Class II by the FDA, indicating that use of the drug may cause “temporary or medically reversible health consequences.” The measure affects products packaged and distributed by Major Pharmaceuticals, with some batches also sold by Cardinal Health across the country.
Risks of treatment with inadequate dosage
Levothyroxine sodium is essential for the treatment of conditions such as hypothyroidism, thyroid cancer and Hashimoto’s disease. The lack of the active ingredient means that patients may not be receiving the correct dosage to manage their condition, which can lead to inappropriate treatment. The consequences, although reversible in most cases, generate concern among users.
Hypothyroidism, for example, is a condition in which the thyroid gland does not produce enough hormones, which are essential for the body’s metabolism. An underpotent medication may not be able to compensate for this deficiency, compromising the health and well-being of individuals who rely on treatment daily.
The anguish of patients who depend on the medication
For many, levothyroxine is more than a medicine; It is a daily pillar for maintaining health. Alexa Cimino, 27, who lost her thyroid to cancer in 2024, described the news as “terrifying”. According to her, trusting the medication is a daily act of faith. “The idea that a dose might not be as strong as it should be is genuinely horrible,” Cimino said, highlighting the blow to confidence that a recall like this causes.
Dependence on the medication to avoid serious complications makes the effectiveness of the dose a matter of safety and quality of life. Uncertainty about the potency of the medicine can generate anxiety and fear, especially for those with a history of serious thyroid-related illnesses.
Critical impact on children and expert guidance
Abeera Hassoun, a pediatric endocrinologist at Columbia University Medical Center, describes levothyroxine as the “bread and butter” of her patients’ treatment plan, especially children with congenital hypothyroidism who start taking it soon after birth. Any change in dosage may affect brain development, growth, and cognitive ability in younger patients. Hassoun noted that children with treatment delays demonstrated “slow” school performance and learning problems.
However, Hassoun emphasizes that regardless of the dosage indicated on the packaging, she and other endocrinologists always perform tests on their patients to ensure they are receiving the correct amount of the medication. The specialist stated that the situation is not “very worrying, as long as I monitor the patients”, which highlights the importance of continuous medical monitoring.
Affected batches and challenges for consumers
The FDA detailed that the recall covers twelve different strengths and packaging, listing specific batches and expiration dates. Although the pills were distributed across the country, the agency’s notice did not specify the exact number of recalled pills that were in circulation.
Difficulty for patients, as highlighted by Hassoun, can arise in accessing alternative branded medicines, which are generally more expensive. Levothyroxine sodium is a more affordable option than Synthroid, for example. If the recall affects insurance coverage for levothyroxine, treatment management could become a “problem,” especially for those with fewer financial resources.
How to identify recalled products
To check whether your medication is among those affected, it is essential to consult the detailed information released by the FDA. The list includes the dosage, batch number (Lot# or Bag lot#) and expiration date for each product.
- Levothyroxine Sodium Tablets, USP, 25 mcg:Lot N02212, expiration date July 2026.
- Levothyroxine Sodium Tablets, USP, 50 mcg:Lot N02200, expiry October 2026.
- Levothyroxine Sodium Tablets, USP, 75 mcg:Lot N02172, expiration date July 2026; Lots N02296 and N02288, expiration date December 2026.
- Other dosages:The complete FDA list includes several other batches for dosages such as 88 mcg, 112 mcg, 125 mcg, 150 mcg, with different expiration dates. Patients are advised to check the NDC (National Drug Code) number and batch and expiration details on the packaging of their medicines.
